Health-related quality of life advantage of long-acting injectable antipsychotic treatment for schizophrenia: a time trade-off study

Table 1 Health-related quality of life (utility) values for varying treatment intervals across demographic categories; gender, age, income and education

		Vignette 1: Untreated	Vignette 2: 2 weeks	Vignette 3: 4 weeks	Vignette 4: 3 months
Gender
Men	Mean	.22	.57	.62	.70
(N = 49)	Median	.20	.60	.63	.75
	SD	.22	.24	.24	.22
	Mean	.32	.65	.69	.71
Women	Median	.25	.70	.75	.80
(N = 49)	SD	.30	.25	.23	.24
	Z	-1.45	-1.7	-1.6	-.5
	p-value	.15	.09	.11	.6
Age (years)
<30	Mean	.23	.59	.65	.70
(N = 25)	Median	.18	.65	.70	.75
	SD	.23	.22	.22	.26
30-50	Mean	.26	.60	.65	.71
(N = 42)	Median	.15	.63	.70	.75
	SD	.24	.24	.23	.22
>50	Mean	.31	.62	.65	.70
(N = 30)	Median	.20	.70	.73	.79
	SD	.32	.29	.27	.27
	Chi-Square	.52	.91	.10	.13
	df	2	2	2	2
	p-value	.8	.6	.9	.9
Income (AUD$)
<30,000	Mean	.27	.62	.67	.71
(N = 36)	Median	.18	.65	.69	.73
	SD	.30	.24	.24	.22
$30,000- $80,000	Mean	.24	.60	.65	.72
(N = 41)	Median	.18	.65	.70	.80
	SD	.24	.27	.24	.25
>$80,000	Mean	.32	.60	.62	.67
(N = 21)	Median	.40	.65	.70	.70
	SD	.24	.23	.23	.22
	Chi-Square	1.7	.16	.70	1.6
	df	2	2	2	2
	p-value	.4	.9	.7	.4
Education
High school or less	Mean	.27	.62	.67	.73
(N = 25)	Median	.20	.68	.70	.80
	SD	.24	.23	.20	.21
TAFE or college	Mean	.27	.61	.67	.68
(N = 30)	Median	.08	.70	.73	.75
	SD	.31	.28	.26	.25
University graduate	Mean	.27	.58	.63	.70
(N = 41)	Median	.20	.60	.70	.75
	SD	.25	.25	.25	.23
	Chi-Square	1.7	.16	.70	1.6
	df	2	2	2	2
	p-value	.4	.9	.7	.4

ISSN: 1477-7525